<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232738</url>
  </required_header>
  <id_info>
    <org_study_id>11922</org_study_id>
    <nct_id>NCT01232738</nct_id>
  </id_info>
  <brief_title>Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yunxia Wang, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Western ALS Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons
      in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and
      loss of muscle function. While there are drugs to help relieve symptoms of ALS, there is no
      cure for ALS.

      Rasagiline is a drug with possible neuroprotective characteristics. Neuroprotective means
      that the nervous system may be protected against weakening. It is known that rasagiline has
      possible neuroprotective characteristics and it is approved for use for patients with another
      disorder, the effectiveness of rasagiline for patients with ALS has not been tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aim of this screen study is to determine whether rasagiline is safe in this
      patient population and if the drug has the potential to slow ALS disease progression
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The primary outcome measure is the difference in the rate of decline in function, as detected by the ALS Functional Rating Scale - Revised (ALSFRS-R) in patients taking rasagiline compared to a database of patients from randomized clinical trials conducted during 1997-2007. Minimum score is 0 (no function) to Maximum score is 48 (normal function)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Time to Treatment Failure</measure>
    <time_frame>up to 12 months</time_frame>
    <description>This group is defined as death, endotracheal intubation, tracheostomy-assisted ventilation or use of noninvasive ventilation &gt;= 23 hours/day for 14 days or more.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in JC-1 Mitochondrial Biomarkers</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>The 12 month change in mitochondrial biomarkerJC-1 red/green fluorescence ratio. We measured at baseline, 6 months and 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mitotracker Mitochondrial Biomarkers</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>The 12 month change in mitochondrial biomarkerMitotracker. We measured at baseline, 6 months and 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Percent Annexin V Mitochondrial Biomarkers</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>The 12 month change in mitochondrial biomarker Annexin V %. We measured at baseline, 6 months and 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in BCL2/BAX Mitochondrial Biomarkers</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>The 12 month change in mitochondrial biomarker BCL2/BAX. We measured at baseline, 6 months and 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in ORAC Mitochondrial Biomarkers</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>rasagiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated for 12 months with rasagiline 2mg orally, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rasagiline</intervention_name>
    <description>rasagiline 2 mg daily for 12 months</description>
    <arm_group_label>rasagiline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A clinical diagnosis of laboratory-supported probable, probable, or definite ALS,
             according to a modified El Escorial criteria, by the study investigator (Appendix IV).

          2. 21 to 80 years of age inclusive.

          3. VC greater or equal to 75% of predicted at screening and baseline.

          4. Onset of weakness within 3 years prior to enrollment.

          5. If patients are taking riluzole for ALS, they must be on a stable dose for at least
             thirty days prior to the baseline visit.

          6. Women of childbearing age must be non-lactating and surgically sterile or using an
             effective method of birth control and have a negative pregnancy test.

          7. Willing and able to give signed informed consent that has been approved by the
             Institutional Review Board (IRB).

        Exclusion criteria

          1. Requirement for tracheotomy ventilation or non-invasive ventilation for &gt; 23 hours per
             day.

          2. Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine,
             phenylpropanolamine, and ephedrine.

          3. Patients on analgesics with serotoninergic properties such as meperidine, tramadol,
             methadone and propoxyphen, flexeril.

          4. Patients on fluoxetine or fluvoxamine.

          5. Patients taking amitriptyline &gt; 50 mg/d, trazodone and sertraline &gt; 100 mg/d,
             citalogram &gt; 20 mg/d or paroxetine &gt; 30 mg/d.

          6. Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease,
             etc).

          7. Clinically significant history of unstable medical illness (unstable angina, advanced
             cancer, etc) over the last 30 days.

          8. History of renal disease.

          9. History of liver disease.

         10. Current pregnancy or lactation.

         11. Limited mental capacity such that the patient cannot provide written informed consent
             or comply with evaluation procedures.

         12. History of recent alcohol or drug abuse or noncompliance with treatment or other
             experimental protocols.

         13. VC &lt; 75% of predicted.

         14. Receipt of any investigational drug within the past 30 days.

         15. Women with the potential to become pregnant who are not practicing effective birth
             control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunxia Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital System</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <results_first_submitted>November 16, 2016</results_first_submitted>
  <results_first_submitted_qc>April 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2018</results_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Yunxia Wang, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rasagiline</title>
          <description>Open label study of rasagiline at 2 mg daily for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rasagiline</title>
          <description>Open label study of 2 mg rasagiline daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)</title>
        <description>The primary outcome measure is the difference in the rate of decline in function, as detected by the ALS Functional Rating Scale - Revised (ALSFRS-R) in patients taking rasagiline compared to a database of patients from randomized clinical trials conducted during 1997-2007. Minimum score is 0 (no function) to Maximum score is 48 (normal function)</description>
        <time_frame>up to 12 months</time_frame>
        <population>The placebo arm are from the randomized, controlled studies in ALS performed during 2004-2010, corrected for symptom duration.</population>
        <group_list>
          <group group_id="O1">
            <title>ALSRFS-R Slope - Rasagiline</title>
            <description>Change in ALSRFS-R at 12 months</description>
          </group>
          <group group_id="O2">
            <title>ALSFRS-R - Historical Placebo Control</title>
            <description>Change in slope in the Historical Placebo Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)</title>
          <description>The primary outcome measure is the difference in the rate of decline in function, as detected by the ALS Functional Rating Scale - Revised (ALSFRS-R) in patients taking rasagiline compared to a database of patients from randomized clinical trials conducted during 1997-2007. Minimum score is 0 (no function) to Maximum score is 48 (normal function)</description>
          <population>The placebo arm are from the randomized, controlled studies in ALS performed during 2004-2010, corrected for symptom duration.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="0.14"/>
                    <measurement group_id="O2" value="-0.94" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in slope of decline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Time to Treatment Failure</title>
        <description>This group is defined as death, endotracheal intubation, tracheostomy-assisted ventilation or use of noninvasive ventilation &gt;= 23 hours/day for 14 days or more.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Failure was defined as death, endotracheal intubation, tracheostomy-assisted ventilation, or use of noninvasive ventilation 23 hours/day for 14 days or more. It is defined in years.</population>
        <group_list>
          <group group_id="O1">
            <title>Difference in Time to Treatment Failure - Rasagiline</title>
            <description>This group is defined as death, endotracheal intubation, tracheostomy-assisted ventilation or noninvasive ventilation &gt;=23 hours/day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Difference in Time to Treatment Failure - Historical Control</title>
            <description>Historical Controls were from the previous ALS trials.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Time to Treatment Failure</title>
          <description>This group is defined as death, endotracheal intubation, tracheostomy-assisted ventilation or use of noninvasive ventilation &gt;= 23 hours/day for 14 days or more.</description>
          <population>Failure was defined as death, endotracheal intubation, tracheostomy-assisted ventilation, or use of noninvasive ventilation 23 hours/day for 14 days or more. It is defined in years.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9367" lower_limit="0.7682" upper_limit="0.9839"/>
                    <measurement group_id="O2" value="0.8963" lower_limit="0.8438" upper_limit="0.9318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in JC-1 Mitochondrial Biomarkers</title>
        <description>The 12 month change in mitochondrial biomarkerJC-1 red/green fluorescence ratio. We measured at baseline, 6 months and 12 months.</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Only 14 subjects that completed the study were able to have this biomarker analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Open label study of rasagiline at 2 mg daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in JC-1 Mitochondrial Biomarkers</title>
          <description>The 12 month change in mitochondrial biomarkerJC-1 red/green fluorescence ratio. We measured at baseline, 6 months and 12 months.</description>
          <population>Only 14 subjects that completed the study were able to have this biomarker analyzed.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.14" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mitotracker Mitochondrial Biomarkers</title>
        <description>The 12 month change in mitochondrial biomarkerMitotracker. We measured at baseline, 6 months and 12 months.</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Open label study of rasagiline at 2 mg daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mitotracker Mitochondrial Biomarkers</title>
          <description>The 12 month change in mitochondrial biomarkerMitotracker. We measured at baseline, 6 months and 12 months.</description>
          <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
          <units>Relative Fluorescent Intensity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.14" lower_limit="31.47" upper_limit="76.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Percent Annexin V Mitochondrial Biomarkers</title>
        <description>The 12 month change in mitochondrial biomarker Annexin V %. We measured at baseline, 6 months and 12 months.</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Open label study of rasagiline at 2 mg daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Annexin V Mitochondrial Biomarkers</title>
          <description>The 12 month change in mitochondrial biomarker Annexin V %. We measured at baseline, 6 months and 12 months.</description>
          <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
          <units>Annexin V %</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.67" lower_limit="-20.3" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in BCL2/BAX Mitochondrial Biomarkers</title>
        <description>The 12 month change in mitochondrial biomarker BCL2/BAX. We measured at baseline, 6 months and 12 months.</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Only 10 subjects that completed the study were able to have this biomarker analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Open label study of rasagiline at 2 mg daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BCL2/BAX Mitochondrial Biomarkers</title>
          <description>The 12 month change in mitochondrial biomarker BCL2/BAX. We measured at baseline, 6 months and 12 months.</description>
          <population>Only 10 subjects that completed the study were able to have this biomarker analyzed.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.24" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in ORAC Mitochondrial Biomarkers</title>
        <description>The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months.</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Open label study of rasagiline at 2 mg daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ORAC Mitochondrial Biomarkers</title>
          <description>The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months.</description>
          <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
          <units>Trolox equivalents</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028.70" lower_limit="681.09" upper_limit="1376.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in ORAC Mitochondrial Biomarkers</title>
        <description>The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months.</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Open label study of rasagiline at 2 mg daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ORAC Mitochondrial Biomarkers</title>
          <description>The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months.</description>
          <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
          <units>umol Trolox equivalents</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028.70" lower_limit="681.09" upper_limit="1376.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in ORAC Mitochondrial Biomarkers</title>
        <description>The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months.</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Open label study of rasagiline at 2 mg daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ORAC Mitochondrial Biomarkers</title>
          <description>The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months.</description>
          <population>Only 17 subjects that completed the study were able to have this biomarker analyzed.</population>
          <units>Trolox equivalents</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028.70" lower_limit="681.09" upper_limit="1376.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rasagiline</title>
          <description>Treated for 12 months with rasagiline 2mg orally, once daily.
rasagiline: rasagiline 2 mg daily for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Fractured pelvic bone</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Lab abnormality (elevated ALT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yunxia Wang</name_or_title>
      <organization>UKansasMCRI</organization>
      <phone>913-588-6970</phone>
      <email>ywang@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

